Ac-SDKP vs TB-500

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is an endogenous tetrapeptide generated from the N-terminus of thymosin beta-4 by the enzyme prolyl oligopeptidase, with further regulation by angiotensin-converting enzyme (ACE), and is characterized by roles in hematopoietic progenitor regulation and anti-fibrotic signaling in renal, cardiac, and vascular tissue. Ac-SDKP inhibits collagen synthesis and fibroblast proliferation, reduces TGF-beta-1-mediated fibrotic signaling, and promotes anti-inflammatory macrophage polarization in preclinical models, suggesting a role in tissue homeostasis downstream of the thymosin beta-4 pathway. Preclinical studies in rodent models of renal fibrosis and systemic lupus erythematosus — predominantly from the NIH-funded Rhaleb and Carretero laboratory at Henry Ford Health — have demonstrated that exogenous Ac-SDKP reduces collagen deposition and inflammatory infiltrate; no human clinical trials have been completed or indexed in PubMed. Ac-SDKP has no FDA approval and no approved indication in any jurisdiction; it is studied as a research compound with a plausible anti-fibrotic mechanism and consistent preclinical evidence, but extrapolation of rodent findings to human therapeutic outcomes has not been validated by any clinical investigation.

TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.

TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 (Tb4), a 43-amino-acid protein with established roles in actin cytoskeleton regulation, wound healing, and tissue repair; no published studies have directly examined TB-500 as a compound in its own right. The Tb4 parent protein promotes actin sequestration and cell migration through beta-thymosin repeat interactions, and generates the anti-fibrotic tetrapeptide Ac-SDKP via enzymatic cleavage; TB-500 is hypothesized to retain a subset of these activities in a shorter, potentially more bioavailable fragment form. All available evidence for TB-500 derives from thymosin beta-4 and Ac-SDKP preclinical research, where animal studies demonstrate tissue-reparative and anti-fibrotic effects in cardiovascular, renal, and musculoskeletal models; human clinical translation has not been established for either the parent compound or the fragment. TB-500 has no FDA approval or regulatory approval in any jurisdiction; its hypothesized activity has not been validated in any published study using the fragment specifically, and it is available only as a research compound with a citation base derived entirely from parent-compound literature. TB-500 is commonly studied in combination with BPC-157 and GHK-Cu in what is referred to as the GLOW research blend, with the rationale that thymosin beta-4 fragment activity — actin sequestration and cell migration support — complements BPC-157's angiogenic properties. The GLOW combination is investigated in research contexts for synergistic tissue repair across musculoskeletal, connective tissue, and wound healing applications. TB-500 is most commonly administered via subcutaneous injection in research contexts, consistent with the injectable format used in Tb4 preclinical studies. Nasal spray delivery of TB-500 — often in combination with BPC-157 — has emerged as an investigational format in research blend products, offering a needle-free alternative for combination protocols; systemic bioavailability data for nasal TB-500 in humans is not established. The BPC-157 and TB-500 combination is among the most widely researched peptide stack pairings for tissue repair, with research rationale based on complementary signaling — BPC-157's angiogenic and nitric oxide pathway effects pairing with TB-500's actin cytoskeleton modulation and cell migration promotion. Preclinical research on this combination suggests additive or synergistic tissue-reparative effects across tendon, muscle, and wound healing models, though no human clinical trials have examined the combination directly. Typical research protocols for the BPC-157 and TB-500 blend use TB-500 at 2–5mg alongside BPC-157 at 250–500mcg per dose, administered subcutaneously 2–5 times per week during an active research phase; nasal spray blend formulations use similar mass ratios. The GLOW blend adds GHK-Cu to this pairing for a three-compound research protocol with an additional collagen synthesis and anti-inflammatory layer.